High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy
- PMID: 30343900
- PMCID: PMC6501221
- DOI: 10.1016/j.cell.2018.09.030
High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy
Erratum in
-
High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy.Cell. 2018 Nov 15;175(5):1443. doi: 10.1016/j.cell.2018.11.003. Cell. 2018. PMID: 30445041 Free PMC article. No abstract available.
Abstract
Although current immune-checkpoint therapy (ICT) mainly targets lymphoid cells, it is associated with a broader remodeling of the tumor micro-environment. Here, using complementary forms of high-dimensional profiling, we define differences across all hematopoietic cells from syngeneic mouse tumors during unrestrained tumor growth or effective ICT. Unbiased assessment of gene expression of tumor-infiltrating cells by single-cell RNA sequencing (scRNAseq) and longitudinal assessment of cellular protein expression by mass cytometry (CyTOF) revealed significant remodeling of both the lymphoid and myeloid intratumoral compartments. Surprisingly, we observed multiple subpopulations of monocytes/macrophages, distinguishable by the markers CD206, CX3CR1, CD1d, and iNOS, that change over time during ICT in a manner partially dependent on IFNγ. Our data support the hypothesis that this macrophage polarization/activation results from effects on circulatory monocytes and early macrophages entering tumors, rather than on pre-polarized mature intratumoral macrophages.
Copyright © 2018 Elsevier Inc. All rights reserved.
Conflict of interest statement
DECLARATION OF INTERESTS
E.W.N is a board director and shareholder of immunoSCAPE Pte.Ltd. M.F is Director, Scientific Affairs and shareholder of immunoSCAPE Pte. Ltd. R.D.S. is a cofounder, scientific advisory board member, stockholder and royalty recipient of Jounce Therapeutics and Neon Therapeutics and is a scientific advisory board member for BioLegend, Codiak Biosciences, Constellation Pharmaceuticals, Lytix Biopharma and NGM Biopharmaceuticals.
Figures







References
-
- Balkwill F, Charles KA, and Mantovani A (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211–217. - PubMed
-
- Biswas SK, and Mantovani A (2010). Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature immunology 11, 889–896. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources